- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2020 MJH Life Sciences and Rheumatology Network. All rights reserved.
RA Quiz: How well does upadacitinib fare as RA treatment?
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.” Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.” Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.” Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.” Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.” Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)
- Vibeke Strand, Michael Schiff, Namita Tundia, et al. “Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.”Arthritis Research and Therapy. December 2, 2019. doi:10.1186/s13075-019-2059-8 (©Valentina,AdobeStock_296476228)